These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19758237)

  • 21. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.
    Lebray P; Nalpas B; Vallet-Pichard A; Broissand C; Sobesky R; Serpaggi J; Fontaine H; Pol S
    Antivir Ther; 2005; 10(6):769-76. PubMed ID: 16218177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Hayashi M; Kataoka Y; Tachikawa K; Koguchi H; Tanaka H
    Diabetes Res Clin Pract; 2009 Nov; 86(2):e19-21. PubMed ID: 19744739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?
    Vezali E; Elefsiniotis I; Mihas C; Konstantinou E; Saroglou G
    J Gastroenterol Hepatol; 2009 Jun; 24(6):1024-9. PubMed ID: 19383078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
    Iacobellis A; Cozzolongo R; Minerva N; Valvano MR; Niro GA; Fontana R; Palmieri O; Ippolito A; Andriulli A
    Dig Liver Dis; 2014 Jul; 46(7):621-4. PubMed ID: 24675038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
    Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
    Mira JA; Gutiérrez-Valencia A; Gil Ide L; Merino D; Rivero A; Ríos-Villegas MJ; Delgado M; González-Serrano M; Collado A; Torres-Tortosa M; Omar M; López-Ruz MA; Macías J; Arponen S; Pineda JA
    Clin Infect Dis; 2009 Oct; 49(8):e84-91. PubMed ID: 19772388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferon alpha and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients.
    Pawelczyk T; Pawelczyk A; Strzelecki D; Rabe-Jablonska J
    Gen Hosp Psychiatry; 2008; 30(6):501-8. PubMed ID: 19061675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
    Arizcorreta A; Brun F; Fernández-Gutiérrez C; García Juárez R; Guerrero F; Pérez-Guzmán E; Girón-González JA
    Clin Microbiol Infect; 2004 Dec; 10(12):1067-74. PubMed ID: 15606633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon - Ribavirin in daily practice.
    Ridruejo E; Adrover R; Cocozzella D; Fernández N; Reggiardo MV
    Ann Hepatol; 2010; 9(1):46-51. PubMed ID: 20308722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
    Mac Nicholas R; Norris S
    Aliment Pharmacol Ther; 2010 May; 31(9):929-37. PubMed ID: 20175767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients.
    Dai CY; Chuang WL; Hsieh MY; Huang JF; Lin YY; Chu PY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antiviral Res; 2010 Feb; 85(2):396-402. PubMed ID: 19931565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment induced leucopenia in hepatitis C and Role of G-CSF in its management.
    Shafi MS; Sheikh NI; Rizvi F; Afzal M; Manzoor S
    J Coll Physicians Surg Pak; 2009 Jun; 19(6):346-9. PubMed ID: 19486571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
    Yu ML; Dai CY; Lee LP; Hsieh MY; Hou NJ; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Antivir Ther; 2006; 11(8):1015-9. PubMed ID: 17302371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.
    Saleh MI; Hindi NN
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Sep; 391(9):953-963. PubMed ID: 29872876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C.
    Iio E; Matsuura K; Nishida N; Maekawa S; Enomoto N; Nakagawa M; Sakamoto N; Yatsuhashi H; Kurosaki M; Izumi N; Hiasa Y; Masaki N; Ide T; Hino K; Tamori A; Honda M; Kaneko S; Mochida S; Nomura H; Nishiguchi S; Okuse C; Itoh Y; Yoshiji H; Sakaida I; Yamamoto K; Watanabe H; Hige S; Matsumoto A; Tanaka E; Tokunaga K; Tanaka Y
    Hum Genet; 2015 Mar; 134(3):279-89. PubMed ID: 25515861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.
    Soza A; Everhart JE; Ghany MG; Doo E; Heller T; Promrat K; Park Y; Liang TJ; Hoofnagle JH
    Hepatology; 2002 Nov; 36(5):1273-9. PubMed ID: 12395340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes.
    Spindelboeck W; Horvath A; Tawdrous M; Schmerböck B; Zettel G; Posch A; Streit A; Jurse P; Lemesch S; Horn M; Wuensch G; Stiegler P; Stauber RE; Leber B; Stadlbauer V
    PLoS One; 2016; 11(3):e0150299. PubMed ID: 26938078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.